Indian equity markets delivered strong long-term returns during Prime Minister Narendra Modi’s tenure, with the Sensex and Nifty gaining ar...

Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...

Indian markets ended the week higher after recovering intraday volatility, with Sensex and Nifty posting modest gains amid hopes of easing ...

JP Morgan has cautioned that India’s FY27 earnings face significant risks from an extended energy and logistics shock linked to the Middle ...

Some valuation ratios are used because they are easy. The PE ratio is one of them. It is simple, familiar, and convenient. Not only for the...

As global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.

Market expert Amit Khurana offers insights on key corporate and regulatory developments. Sun Pharma's acquisition is seen as strategically ...

Smallcap valuations seem high but underlying fundamentals have improved. Aditya Khemani of Invesco Mutual Fund sees this as a structural sh...

The March quarter earnings season arrives at an inflection point, with stable numbers masking underlying economic shifts. Escalation of the...

Indian markets are experiencing a temporary disruption, not a fundamental shift. Bajaj Finserv AMC's Nimesh Chandan sees this as a chance t...

Sun Pharma focuses on compliance across its manufacturing units. It aims for full regulatory resolution at facilities facing USFDA action. ...

A senior official of the Pharmexcil said drugs such as Merck's Pembrolizumab (Keytruda) whose revenue were at USD 25 billion and Bristol-My...

Overall in terms of portfolio construction, I would prefer financials as the top pick that will continue to do well, said Bagga.

Vaccines to combat the pandemic and a thrust on diagnostics are near-term drivers. An uptick in acute drugs and business as usual at hospit...

Incidentally, India’s biggest pharma initial public offering capitalised on both these aspects. Last month, a Hyderabad based injectables c...

The stock was listed on November 20, and since then has ended lower in one session.

ALL POSITIVES fully priced in, which leaves little on the table; Chinese ownership comes with growth opportunities and potential shocks